Skip to main content

clinical_trial_results

Amgen's Repatha Cuts Death Risk 20% in High-Risk Heart Trial

Amgen's Repatha Cuts Death Risk 20% in High-Risk Heart Trial

MUNICH, Germany -- August 31, 2026 -- Amgen's Repatha (evolocumab) reduced all-cause mortality by 20% in high-risk patients who had never suffered a heart attack or stroke, according to a pre-specified analysis of the Phase 3 VESALIUS-CV trial presented at the European Society of Cardiology Congress 2026 and published simultaneously in Circulation.

Trial data show mortality benefit emerging after 18 months of treatment
The analysis tracked more than 12,000 high-risk adults over a median of 4.6 years. Both overall deaths and cardiovascular deaths declined in the Repatha arm, with the survival curve separating at approximately 1.5 years and widening through follow-up. Amgen positions this as the first Phase 3 evidence that a PCSK9 inhibitor lowers all-cause mortality in a primary-prevention population.

Amgen's Repatha Cuts Death Risk 20% in High-Risk Prevention Trial

Amgen's Repatha Cuts Death Risk 20% in High-Risk Prevention Trial

THOUSAND OAKS, Calif. -- September 01, 2026 -- Amgen said its cholesterol drug Repatha reduced the risk of death by 20% among more than 12,000 high-risk adults who had not yet suffered a heart attack or stroke, based on a pre-specified analysis of the Phase 3 VESALIUS-CV trial. The company presented the data in a late-breaking session at the European Society of Cardiology Congress 2026 in Munich, Germany, and published the findings simultaneously in Circulation. Amgen said the result marks the first time a PCSK9 inhibitor has shown a reduction in all-cause mortality among primary prevention patients in a Phase 3 study.